DESTINY-Breast03: Trastuzumab Deruxtecan vs Trastuzumab Emtansine in Previously Treated HER2+ Metastatic Breast Cancer

September 16-21, 2021; Virtual
In a head-to-head trial in patients with previously treated HER2-positive metastatic breast cancer, trastuzumab deruxtecan reduced risk of disease progression or death by 72% compared with trastuzumab emtansine, a current standard of care.
Format: Microsoft PowerPoint (.ppt)
File Size: 288 KB
Released: September 23, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Exelixis, Inc.
Ipsen Biopharmaceuticals, Inc.

Related Content

Commentary from Dr. Sunil Badve on Ki67 testing for patients with early-stage hormone receptor-positive/HER2-negative breast cancer from the American Society of Clinical Pathology (ASCP) and Clinical Care Options (CCO)

person default Sunil Badve, MD, FRCPath Released: December 28, 2021

Downloadable summary slideset with key data from the 2021 SABCS Symposium from Clinical Care Options (CCO)

Released: December 16, 2021

From Clinical Care Options (CCO), experts review key data in genitourinary, gastrointestinal, breast, and lung cancers presented at the ESMO 2021 congress

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: December 15, 2021 Expired: December 14, 2022

In this commentary from Clinical Care Options (CCO), experts look ahead to key studies being reported at SABCS 2021 and highlight what data they are most excited to see

Joyce O'Shaughnessy, MD Sara Tolaney, MD, MPH Released: December 6, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings